Loading…
Employees: 1,439
Size Chongqing Pharscin Pharmaceutical (002907.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $808M, the 2733rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.94 on 6 Nov 2026.
Performance Over six months the shares fell 7.2%, against -10.2% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 8.5% over the last twelve months (peer median +2.8%); the operating margin is 9.7% (peer median 10.4%).
Valuation It trades at 5.7× enterprise value to sales against a peer median of 2.5× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥839M | CN¥814M | CN¥763M | CN¥681M | CN¥773M |
| Revenue growth | — | +7% | +12% | -12% | — |
| Gross profit | CN¥509M | CN¥426M | CN¥402M | CN¥344M | CN¥440M |
| EBITDA | n/a | CN¥141M | CN¥148M | CN¥110M | CN¥170M |
| Net income | CN¥93.8M | CN¥65.1M | CN¥76.7M | CN¥32.7M | CN¥98.4M |
| Free cash flow | CN¥89.7M | CN¥53.5M | CN¥149M | CN¥127M | -CN¥44.3M |
| Capital expenditure | CN¥35.7M | CN¥14.6M | CN¥16.2M | CN¥92.8M | CN¥60.6M |
| Total debt | CN¥2.86M | CN¥41.8M | CN¥127,562 | CN¥281,958 | CN¥169,881 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002907.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.8% | -3.6% | 8th lowest of 20 |
| 6-month return | -7.2% | -10.2% | 7th highest of 19 |
| Distance from 52-week high | -29.9% | -33.6% | 6th highest of 20 |
| Revenue growth (TTM) | +8.5% | +2.8% | 7th highest of 18 |
| Operating margin | 9.7% | 10.4% | 9th lowest of 18 |
| EV / Sales | 5.7× | 2.5× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 10.7% | -1.1% | 4th most demanding of 12 |
| Growth delivered (Del g) | -1.4% | +2.1% | 2nd lowest of 12 |
| Hurdle (Req g minus delivered) | +12.0 pp | -4.5 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | +4.8 pp | -0.4 pp | 5th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 8.1× | 17.1% | +22.7% |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 1.2× | -10.5% | +1.9% |